Greg Babcock | Executive Director, Research
Visterra
Appearances:
Day 1 Antibody Congress @ 12:20
Binding strategies for infectious diseases
Plenary
Moderator: Greg Babcock, Executive Director, Research, Visterra
Day 1 Antibody Congress @ 17:25
Designing and engineering antibody therapeutics for difficult-to-target proteins
Plenary- Viral and bacterial proteins are mutable leading to antibody escape
- Human proteins such as GPCRs and ion channels are poorly accessible to antibodies and have dynamic structures that alter epitope conformation and availability
- Identifying and targeting conserved, functionally relevant, accessible epitopes on numerous proteins remains challenging
- The Visterra Heirotope platform harmonizes structural, computational and experimental approaches to engineer antibodies to effectively engage these difficult targets
Greg Babcock, Executive Director, Research, Visterra
Moderator: Greg Babcock, Executive Director, Research, Visterra
- Viral and bacterial proteins are mutable leading to antibody escape
- Human proteins such as GPCRs and ion channels are poorly accessible to antibodies and have dynamic structures that alter epitope conformation and availability
- Identifying and targeting conserved, functionally relevant, accessible epitopes on numerous proteins remains challenging
- The Visterra Heirotope platform harmonizes structural, computational and experimental approaches to engineer antibodies to effectively engage these difficult targets
Greg Babcock, Executive Director, Research, Visterra
Organiser
